Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to -$1.3 million.

  • Anika Therapeutics' Change in Receivables rose 7292.32% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 12383.45%. This contributed to the annual value of -$3.4 million for FY2024, which is 35793.1% down from last year.
  • As of Q3 2025, Anika Therapeutics' Change in Receivables stood at -$1.3 million, which was up 7292.32% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Change in Receivables ranged from a high of $6.2 million in Q2 2023 and a low of -$4.8 million during Q3 2024
  • Its 5-year average for Change in Receivables is $412210.5, with a median of $1.1 million in 2023.
  • As far as peak fluctuations go, Anika Therapeutics' Change in Receivables soared by 28552.71% in 2021, and later plummeted by 95926.89% in 2023.
  • Quarter analysis of 5 years shows Anika Therapeutics' Change in Receivables stood at -$2.1 million in 2021, then surged by 130.74% to $647000.0 in 2022, then surged by 70.63% to $1.1 million in 2023, then surged by 196.38% to $3.3 million in 2024, then tumbled by 139.55% to -$1.3 million in 2025.
  • Its last three reported values are -$1.3 million in Q3 2025, $2.4 million for Q2 2025, and -$3.0 million during Q1 2025.